10,000 Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Purchased by Congress Wealth Management LLC DE

Congress Wealth Management LLC DE bought a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,000 shares of the company’s stock, valued at approximately $414,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. KLP Kapitalforvaltning AS acquired a new position in Mirum Pharmaceuticals during the 4th quarter valued at approximately $277,000. Teacher Retirement System of Texas boosted its holdings in shares of Mirum Pharmaceuticals by 19.7% during the fourth quarter. Teacher Retirement System of Texas now owns 10,613 shares of the company’s stock valued at $439,000 after acquiring an additional 1,748 shares during the period. Swiss National Bank grew its position in shares of Mirum Pharmaceuticals by 1.9% during the fourth quarter. Swiss National Bank now owns 70,300 shares of the company’s stock worth $2,907,000 after acquiring an additional 1,300 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Mirum Pharmaceuticals by 162.6% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 176,960 shares of the company’s stock worth $7,317,000 after acquiring an additional 109,585 shares during the period. Finally, AlphaQuest LLC lifted its position in Mirum Pharmaceuticals by 969.6% in the 4th quarter. AlphaQuest LLC now owns 1,829 shares of the company’s stock valued at $76,000 after purchasing an additional 1,658 shares during the last quarter.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ MIRM opened at $45.99 on Friday. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $54.23. The firm has a market cap of $2.25 billion, a P/E ratio of -22.77 and a beta of 1.04. The stock has a fifty day moving average price of $48.01 and a two-hundred day moving average price of $43.86. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $99.41 million for the quarter, compared to the consensus estimate of $96.64 million. Research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MIRM has been the subject of several recent analyst reports. HC Wainwright upped their target price on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Robert W. Baird raised their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research report on Thursday, February 27th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $58.20.

Insider Activity at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 27,279 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the completion of the sale, the chief executive officer now directly owns 138,641 shares of the company’s stock, valued at $6,129,318.61. This represents a 16.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $32,115.00. Following the completion of the transaction, the senior vice president now directly owns 2,926 shares in the company, valued at $125,291.32. This represents a 20.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 133,679 shares of company stock valued at $6,007,081 over the last ninety days. Insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.